drugset / Trial / NCT01759888
Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
Phase 2
Completed
49 enrolled
Chang Gung Memorial Hospital
National Science and Technology Council, Taiwan · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the investigators will analyze progression rate of genetic-proving PARK8 and PARK6 patients who have homogeneous phenotype and genotype by 18F-DTBZ PET imaging.
Timeline
- Start
- 2011-08
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DTBZ | Diagnostic / imaging agent | 1e-05 mmol | Intravenous |
| Subject | 18F-DTBZ | Diagnostic / imaging agent | 370 mbq | Intravenous |